Dr. Alon Yaar, DVM, MBA
CEO  

Dr. Yaar has extensive hands-on experience in leading R&D in biotechnology, pharmaceuticals and medical devices from very early research stages to production and advanced clinical trials. Alon is a serial entrepreneur with proven management skills and a successful track record. Prior to joining KidneyCure, Dr. Yaar founded and served as CEO and COO of NeuroDerm (NASDAQ:NDRM) acquired by Mitsubishi Tanabe in 2017 in a $1.1billion deal. Alon has also founded Touch Brain Ltd., Neuroptic Ltd., Science in Action Ltd. and Youdim Pharmaceuticals Incubator.

Avraham Hermon, MA
Patent Attorney

Mr. Hermon is an Israeli Patent Attorney and a US Patent Agent. He has over 15 years of experience in leading patent firms and as in-house counsel supporting the intellectual property needs of companies and universities in a variety of fields including innovative pharmaceuticals, biotech and medical devices. Before joining  KidneyCure, Avraham has served as Senior Manager at Teva  Pharmaceutical Industries Global  Patent Group, IP Director at Youdim Pharmaceuticals Ltd., and Patent Attorney at the firm JMB Davis Ben-David.

Prof. Benjamin Dekel, MD, PhD
​Chief Scientific and Medical Advisor

Prof. Dekel is a world renowned authority in Nephrology, human renal progenitor cells and renal regenerative medicine. The scientific basis and motivation for KidneyCure was created by Prof. Dekel in his research laboratory at the Sheba Medical Center, Israel, one of the leading medical centers in the world. The author of more than 100 scientific publications and the principal inventor of KidneyCure's core cellular technologies, Prof. Dekel currently serves as the Head of the Paediatric Stem Cell Research Institute, Professor of Pediatrics, and Director  of the Division of Paediatric Nephrology Edmond & Lily Safra Children's Hospital at Sheba Center for Regenerative Medicine. He is also a Professor at Sackler School of Medicine, Tel Aviv University and the President of Israel Stem Cell Society.

Inna Martin, BA, MBA
Head of Business Development

Mrs. Martin brings to KidneyCure more than 17 years of experience in healthcare innovation and Venture Capital fields. Prior to joining KidneyCure, Inna served as an Investment Director at RMI Partners VC as well as a Member of the Board of ReVision Optics Inc., Ocunexus Inc., and Ocon Medical Ltd. Mrs. Martin also served as a strategic business development and financial consultant to Israel’s leading biomed and pharma-focused Venture Capital firms in addition to other companies including NASDAQ traded companies in the US and Canada, TASE traded biotech and MedTech companies.  

Yechiel Goldman, PhD
Project Manager 

Yechiel has more than 15 years of experience as a regulatory affairs professional in the pharma, biotech and cell therapy industries.  Prior to joining KidneyCure, Yechiel served as Manager in the Global Regulatory Affairs Dept., IR&D Division at Teva Pharmaceuticals, and founded Bikorei HaKerem Regulatory & Scientific Writing.

Dr. Orit Steinberg, PhD
Senior Researcher

Dr. Steinberg, Senior Researcher and Regenerative Medicine Research Lab Manager at the Sheba Pediatric Stem Cell Research Institute, brings to the company 20 years of active, hands-on experience in cell biology. She led the initial research of the kidney cell-based therapeutic technologies at Prof. Dekel’s Laboratory in the Sheba Medical Center. Dr. Steinberg’s deep knowledge of the origins of these technologies and experience plays an important role in developing CMC processes and cell culturing methods.

Dr. Masha Simanovsky, PhD 
Operations Leader 

Dr. Simanovsky brings to KidneyCure 20 years of hands-on experience in the research and development of innovative cell therapies including development of tissue culture methods, transfection, cell selection, infection and development of proliferation assays. Previously, Masha served as a Project Manager at Solubest Ltd. and Researcher at the Laboratory of Molecular Immunobiology, Bone Marrow Transplantation Department of Sheba Medical Center, and Researcher at Orgenix, one the pioneers and great success stories of the Israeli biotech industry.

Dr. Sabina Glozman, PhD, MEI
Product Strategy 

Dr. Glozman has 20 years of serial entrepreneurship and  executive management experience in translation of research projects towards GLP, GMP and GCP-compliant product development pathways. Prior to joining KidneyCure, Dr. Glozman served as CEO of Biological Industries Ltd., Beit Haemek, a global GMP cell reagents manufacturer and supplier as well as a distributor of Promega, ATCC and Sartirius in Israel. Under her management the company expanded its facilities and introduced several stem cell culture  products for various therapeutic indications into the market. Sabina also served as CEO of Accelta Ltd., Technion and Avita International Ltd. Cellavita In SP Brazil, CEO of Solubest Ltd., and VP of Business Development at Protalix Ltd. (PLX:US NYSE MKT).  Dr. Glozman also lead business and strategic consulting projects at Ben Gurion University and the Biotechnology Institute, Haifa University, Goji Ltd., and Immune Therapeutics Inc.

BOARD OF DIRECTORS & INVESTORS

KidneyCure is supported by a strong group of investors including Mr. Jonathan Leitersdorf , Prof. John Finberg, Direct Insurance Financial Investments, Gilad Altshuler Holdings and Aurum Ventures VC.

Dr. Oded Ben-Joseph, Ph.D., MBA,

Outcome Capital 

Dr. Alon Yaar, DVM, MBA, KidneyCure 

Dr. Ben-Joseph is Managing Director with Outcome Capital, a life science investment banking firm focusing on private equity and merger and acquisition in the therapeutic medical technology sector. He brings a unique combination of executive, entrepreneurial, scientific and transactional experience and is passionate about assisting cutting-edge life sciences companies in enhancing their strategic value and developing a path to successful liquidity.

Ran Avnat LL.B,

Wolfson Clore Mayer

Adv. Ran Avnat has over 15 years of experience in leading and supporting legal and business operations of companies in the life sciences, medical devices and real estate fields. He serves as the General Counsel of Wolfson Clore Mayer, a holding and investment company founded in 1961 which encompasses a broad cross-section of activities, mainly in real estate and life sciences.

Jonathan Leitersdorf, BA, M Sc, MA, Laramie Investment Holding, V.I.

Mr. Leitersdorf holds a Master of Architecture from the Architectural Association, School of Architecture, London and Masters of Science and Real Estate Development from Columbia University, New York City. He is the Trustee of Laramie Investment Holding, V.I. and the representative of the family that is the principal shareholder of Neurogenic Ltd. which is developing a diagnostic kit for schizophrenia. 

Dr. Yaar has extensive hands-on experience in leading R&D in biotechnology, pharmaceuticals and medical devices from very early research stages to production and advanced clinical trials. Alon is a serial entrepreneur with proven management skills and a successful track record. Prior to joining KidneyCure, Dr. Yaar founded and served as CEO and COO of NeuroDerm (NASDAQ:NDRM) acquired by Mitsubishi Tanabe in 2017 in a $1.1billion deal. Alon has also founded Touch Brain Ltd., Neuroptic Ltd., Science in Action Ltd. and Youdim Pharmaceuticals Incubator.

Prof. Benjamin Dekel 

Prof. Dekel is a world known expert in Nephrology, Human Renal Cells and Renal Regenerative Medicine. He is the author of more than 100 scientific publications and principal inventor of KidneyCure's core cellular technologies. He currently serves as the Head of the Paediatric Stem Cell Research Institute, Professor of Pediatrics, and Director  of the Division of Paediatric Nephrology Edmond & Lily Safra Children's Hospital at Sheba Center for Regenerative Medicine. He is also a Professor at Sackler School of Medicine, Tel Aviv University and the President of Israel Stem Cell Society. 

KidneyCure Ltd.

Phone: +972-54-453-4340

Address: 9 Ahad Ha’am, Tel Aviv, Israel

© 2018 KidneyCure Ltd. All rights reserved.